GEN Exclusives

More »

GEN News Highlights

More »
Jul 21, 2009

GSK and Enigma to Develop Point-of-Care Flu Diagnostic

  • GlaxoSmithKline (GSK) and Enigma Diagnostics inked a pact to a provide point-of-care influenza test. As per the worldwide agreement, the diagnostic will be developed on Enigma’s PCR technology, the Enigma ML (mini laboratory).

    GSK will reportedly make a small equity investment in Enigma, pay an up-front fee, and provide R&D funding. Further payments will be subject to development progress and agreed milestones, and the companies will share profits.

    A trial involving working prototypes of the ML system with front-line healthcare providers across Europe will commence in the fourth quarter. Launch of Enigma ML is anticipated in early 2011.

    The aim is to be able to test for specific flu subtypes and deliver fully automated results from swab samples in less than 60 minutes with the same accuracy as reference labs. Operators of the Enigma ML system will not require specialist training, according to the companies.

     

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?